OncoSil Medical (ASX:OSL) YoY EPS Growth: 64.20% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:OSL OncoSil Medical Ltd ASX:OSL
44 GF Score
Price A$1.22
GF Value A$2.92
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is OncoSil Medical YoY EPS Growth?

OncoSil Medical ASX:OSL -9.29% 44 YoY EPS Growth is 64.20% as of Dec. 2025. GuruFocus rates ASX:OSL with a GF Score™ of 44/100 and a GF Value™ of A$2.92 (Possible Value Trap). The stock has 4 warning signs investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. OncoSil Medical's YoY EPS Growth for the quarter that ended in Dec. 2025 was 64.20%.

OncoSil Medical's Earnings per Share (Diluted) for the six months ended in Dec. 2025 was A$-0.24.

OncoSil Medical YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for OncoSil Medical's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoSil Medical YoY EPS Growth Chart

OncoSil Medical Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -96.89 -4.41 6.78 40.71 38.30

OncoSil Medical Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.23 45.46 40.02 36.55 64.20
ASX:OSL
44GF Score
OncoSil Medical Ltd ASX:OSL
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OncoSil Medical YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

OncoSil Medical's YoY EPS Growth for the fiscal year that ended in Jun. 2025 is calculated as:

YoY EPS Growth (A: Jun. 2025 )
=(Earnings per Share (Diluted) (A: Jun. 2025 )-Earnings per Share (Diluted) (A: Jun. 2024 ))/ | Earnings per Share (Diluted) (A: Jun. 2024 ) |
=(-1.374--2.227)/ | -2.227 |
=38.30 %

OncoSil Medical's YoY EPS Growth for the quarter that ended in Dec. 2025 is calculated as:

YoY EPS Growth (Q: Dec. 2025 )
=(Earnings per Share (Diluted) (Q: Dec. 2025 )-Earnings per Share (Diluted) (Q: Dec. 2024 )) / | Earnings per Share (Diluted) (Q: Dec. 2024 )) |
=(-0.242--0.676)/ | -0.676 |
=64.20 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of 64.20% mean?
OncoSil Medical (ASX:OSL) has a YoY EPS Growth of 64.20% as of Dec. 2025. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for OncoSil Medical and its competitors.
Is OncoSil Medical's YoY EPS Growth too high?
OncoSil Medical's current YoY EPS Growth is 64.20%. Overall, OncoSil Medical has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does OncoSil Medical's YoY EPS Growth compare to ABT and SYK?
OncoSil Medical's YoY EPS Growth of 64.20% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Medical Devices & Instruments company?
A good YoY EPS Growth depends on the Medical Devices & Instruments industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for OncoSil Medical and its competitors. OncoSil Medical's current YoY EPS Growth is 64.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoSil Medical stock overvalued right now?
Based on GuruFocus' analysis, OncoSil Medical (ASX:OSL) is currently considered Possible Value Trap. The stock's GF Value™ is A$2.92, compared to a current price of A$1.22 — trading 58.2% below its estimated fair value. The current YoY EPS Growth is 64.20%. OncoSil Medical's overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For OncoSil Medical (ASX:OSL), the current YoY EPS Growth is 64.20% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OncoSil Medical (ASX:OSL) Overvalued in 2026?

Based on GuruFocus' analysis, OncoSil Medical stock appears to be undervalued. The current stock price of A$1.22 is trading 58.2% below its estimated GF Value™ of A$2.92. GuruFocus considers OncoSil Medical to be Possible Value Trap.

Key valuation signals for ASX:OSL:

  • YoY EPS Growth: 64.20%
  • GF Value™: A$2.92 vs. price of A$1.22 (58.2% below fair value)
  • GF Score™: 44/100 with 4 warning signs

No single metric tells the full story. See the ASX:OSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OncoSil Medical Business Description

Address 7 Eden Park Drive, Level 5, Macquarie Park, Sydney, NSW, AUS, 2113
OncoSil Medical Ltd is a medical device company. It is engaged in the development and commercialization of its product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. It operates in one segment. the device development for new medical treatments. Geographically, the company derives its maximum revenue from Europe and the rest from Australia and New Zealand.
44GF Score

Get the complete analysis for ASX:OSL

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.22
Price
A$2.92
GF Value